التفاصيل البيبلوغرافية
| العنوان: |
Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting. |
| المؤلفون: |
Birkner, Benjamin, Rech, Jürgen, Edelmann, Edmund, Verheyen, Frank, Schett, Georg, Stargardt, Tom |
| المصدر: |
Rheumatology; Apr2023, Vol. 62 Issue 4, p1476-1484, 9p |
| مصطلحات موضوعية: |
DISEASE progression, CONFIDENCE intervals, TIME, HEALTH outcome assessment, MEDICAL care costs, ANTIRHEUMATIC agents, TREATMENT effectiveness, HEALTH insurance reimbursement, COMPARATIVE studies, RHEUMATOID arthritis, DRUG therapy, MEDICAL records, DECISION making, KAPLAN-Meier estimator, DESCRIPTIVE statistics, RESEARCH funding, MEDICAL practice, TERMINATION of treatment, LONGITUDINAL method, DISEASE remission, PROPORTIONAL hazards models, EVALUATION |
| مصطلحات جغرافية: |
GERMANY |
| مستخلص: |
Objective We aim to provide real-world evidence on the effectiveness of patient-individual tapering of DMARDs for patients with RA in daily clinical practice using medical records and claims data. Methods We utilize data obtained through a controlled prospective cohort study in Germany conducted from July 2018 to March 2021. Participants consist of RA patients in sustained remission (>6 months) who were eligible for tapering at enrolment. Patients treated with individual tapering based on shared decision making (n = 200) are compared with patients without any dose reduction (n = 237). The risk of loss of remission and the risk of flare is assessed with risk-adjusted Kaplan–Meier estimators and Cox regressions. We evaluate differences in costs 1 year before and after baseline based on claims data for the subgroup of patients insured at one major sickness fund in Germany (n = 76). Results The risk of flare (hazard ratio 0.88, 95% CI 0.59, 1.30) or loss of remission (hazard ratio 1.04, 95% CI 0.73, 1.49) was not statistically different between the individual tapering group and the continuation group. Minor increases of disease activity and decreases of quality of life were observed 12 months after baseline, again with no statistically significant difference. Drug costs decreased by 1017€ in the individual tapering group while they increased by 1151€ in the continuation group (P < 0.01). Conclusion Individual tapering of DMARDs does not increase the average risk of experiencing flares or loss of remission. Encouraging rheumatologists and patients to apply tapering in shared decision making may be a feasible approach to allow individualization of treatment in RA. [ABSTRACT FROM AUTHOR] |
|
Copyright of Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder